Despite the contradicting indications of AHR agonists vs. AHR antagonists as well as the incomplete understanding of the pleiotropic role of AHR in the control of inflammation, tumorigenesis, and cancer immunity, the clinical translation of both AHR agonists and AHR antagonists has started, with hope for triumphant success in the coming years. This evidence concerns the gene AHR and cancer.